506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
T-ALL, T-NHL (Lymphoblastic)
Interventions
DRUG

Nelarabine

1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5

Trial Locations (11)

13125

HELIOS Klinikum Berlin-Buch, Berlin

24105

Universitätsklinikum Kiel, Kiel

30625

Medizinische Hochschule Hannover, Hanover

45147

Universitätsklinikum Essen, Essen

48149

Universitätsklinik Münster, Münster

60590

University Hospital of Frankfurt, Medical Dept. II, Frankfurt am Main

70376

Robert Bosch Krankenhaus, Stuttgart

93042

Klinikum der Universität Regensburg, Regensburg

01307

Universitätsklinik Dresden, Dresden

04103

Universitätsklinikum Leipzig, Leipzig

07747

Klinikum der FSU Jena, Jena

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Goethe University

OTHER

NCT00684619 - 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) | Biotech Hunter | Biotech Hunter